Bone News and Research

RSS

New partnership to create Translational Orthopedic Research Program

The creation of the Translational Orthopedic Research Program (TORP), a new partnership of Van Andel Research Institute (VARI) and its affiliate the Translational Genomics Research Institute (TGen), Spectrum Health, Orthopaedic Associates of Michigan (OAM), and the Michigan State University (MSU) College of Human Medicine, was announced today by officials of the sponsoring organizations who gathered at Van Andel Institute for the World Osteoporosis Day Summit, a meeting spotlighting local osteoporosis efforts.

22 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

Philadelphia's Franklin Institute to exhibit Gunther von Hagens' Body Worlds 2 & The Brain

Gunther von Hagens' Body Worlds 2 & The Brain made its debut at Philadelphia's Franklin Institute on October 17, and will be one of many points of interest for visitors eager to explore the area's vast array of scientific treasures.

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Physicists, chemists and engineers at the University of Pennsylvania have demonstrated a novel method for the controlled formation of patchy particles, using charged, self-assembling molecules that may one day serve as drug-delivery vehicles to combat disease and perhaps be used in small batteries that store and release charge.

21 Oct 2009

Lactose intolerance rates may be overestimated by wide margins

Prevalence of lactose intolerance may be far lower than previously estimated, according to a study in the latest issue of Nutrition Today.(1) The study, which uses data from a national sample of three ethnic groups, reveals that the overall prevalence rate of self-reported lactose intolerance is 12 percent - with 7.72 percent of European Americans, 10.05 percent of Hispanic Americans and 19.5 percent of African Americans who consider themselves lactose intolerant.

21 Oct 2009

Osteologix to continue clinical development of NB S101 osteoporosis drug

Osteologix, Inc., a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.

21 Oct 2009

Assets of Cartilix acquired by Biomet

Biomet, Inc., a global leader in the manufacture of orthopedic and dental medical devices, announced today its acquisition of the assets of Cartilix, a Foster City, CA based company that has developed proprietary cartilage repair technology.

21 Oct 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Children having accelerated bone growth at an increased risk of hypertension

Children whose bones are "older" than their chronological age may be at an increased risk of hypertension, according to a study reported today (19 October) in Hypertension: Journal of the American Heart Association.

20 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Vertos Medical raises $15.5 million for U.S. commercialization of the company’s "mild" technology

Medical device company Vertos Medical, Inc., developer of the mild® procedure for lumbar spinal stenosis (LSS), today announced it has completed a $15.5 million Series D financing. New investor, ONSET Ventures, led the round with additional participation from existing Vertos investors CHL Medical Partners, Foundation Medical Partners, Aweida Venture Partners and DFJ Mercury.

20 Oct 2009

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Speaking in Rome, Italy today on the occasion of World Osteoporosis Day, International Osteoporosis Foundation (IOF) CEO Patrice McKenney called for individuals and governments around the globe to join the fight against osteoporosis. "Osteoporosis is a common but devastating disease which we cannot afford to ignore. Immediate measures must be taken to reduce the burden of osteoporotic fractures through prevention, early recognition of fracture risk, and appropriate proven treatment for those in need," she urged.

20 Oct 2009

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience's 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Faces don't lie when it comes to showing signs of aging. Yet gravity alone is not the sole determinant of the aging face. Studies have demonstrated that volume loss of soft tissue and bone is at least equally important to facial aging. The loss of volume in the face over time can cause deep lines, sunken areas around the eyes, temples, nose and jowls.

20 Oct 2009

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

20 Oct 2009

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Mother Nature has provided the lizard with a unique ability to regrow body tissue that is damaged or torn ― if its tail is pulled off, it grows right back. She has not been quite so generous with human beings. But we might be able to come close, thanks to new research from Tel Aviv University.

20 Oct 2009

Bone News and Research

New partnership to create Translational Orthopedic Research Program

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Philadelphia's Franklin Institute to exhibit Gunther von Hagens' Body Worlds 2 & The Brain

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Lactose intolerance rates may be overestimated by wide margins

Osteologix to continue clinical development of NB S101 osteoporosis drug

Assets of Cartilix acquired by Biomet

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Children having accelerated bone growth at an increased risk of hypertension

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Vertos Medical raises $15.5 million for U.S. commercialization of the company’s "mild" technology

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

NCCN Guidelines for Acute Myeloid Leukemia updated

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News